Key Developments For Vascular Solutions Inc
Vascular Solutions Inc (VASC.O) (Consolidated Issue listed on NASDAQ Global Market)
Vascular Solutions, Inc. Announces 510(k) Clearance And U.S. Launch Of GuideLiner Catheter
Vascular Solutions, Inc. announced that it has received 510(k) clearance from the U.S. Food & Drug Administration to launch the GuideLiner catheter in the United States. The GuideLiner is a coaxial mother and child guide extension with rapid exchange convenience that provides back-up support and selective deep intubation in challenging coronary interventions. The GuideLiner catheter will be available in 6, 7 and 8 French sizes as part of Vascular Solutions' specialty catheter product line. CE mark clearance of the GuideLiner was received and European sales and clinical uses commenced in October, with the U.S. launch of the GuideLiner catheter expected to commence in November through Vascular Solutions' direct sales force.
Vascular Solutions, Inc. Issues Q4 2009 Outlook; Revenue Outlook Below Analysts' Estimates; Reiterates FY 2010 Revenue Outlook
Vascular Solutions, Inc. announced that for fourth quarter of 2009, it expects net revenue to be between $17.9-$18.3 million and net income per fully diluted share (EPS) to be between $0.09-$0.11. For fiscal 2010, it expects sales to continue to grow between 11%-13% over fiscal 2009. According to Reuters Estimates, analysts were expecting the Company to report revenues of $18.5 million and EPS of $0.11 for fourth quarter of 2009 and revenues of $77 million for fiscal 2010.
Vascular Solutions, Inc. And Zerusa Limited Announce FDA Market Clearance for Guardian II Hemostasis Valve
Vascular Solutions, Inc. and Zerusa Limited announced that they have received 510(k) clearance with the FDA for the sale of the Guardian II Next Generation hemostasis valve in the United States. Under the terms of an agreement between the two companies from July 2007, Vascular Solutions is the exclusive distributor of the Guardian device in the United States. Zerusa recently began the rollout of its CE marked Guardian II launch through its distribution network in Europe, the Middle East and other markets.
Vascular Solutions, Inc. Issues Q3 2009 Mixed Guidance
Vascular Solutions, Inc. announced that for the third quarter of 2009, it expects revenue to be between $17.1 million and $17.5 million and net income on a fully-taxed basis to be between $0.08 and $0.09 per fully diluted share (EPS). According to Reuters Estimates, analysts on an average were expecting the Company to report revenue of $17.0 million and EPS of $.10 for the third quarter of 2009.
Vascular Solutions, Inc. Issues Q2 2009 Guidance; Revenue Guidance Below Analysts' Estimates; Lowers FY 2009 Guidance
Vascular Solutions, Inc. announced that for the second quarter of 2009, it expects revenue to increase to between $16.6 and $17.0 million. Net income in the second quarter of 2009 on a fully-taxed basis is expected to be between $0.07 and $0.09 per fully diluted share (EPS). Principally as the result of the suspension of the Thrombi-Paste clinical development, the Company is adjusting its fiscal 2009 guidance for net revenue to between $67 and $70 million and net income per diluted share on a fully-taxed basis to be between $0.30 and $0.34. According to Reuters Estimates, analysts on an average were expecting the Company to report EPS of $0.08 on revenue of $17.5 million for the second quarter of 2009; and EPS of $0.35 on revenue of $71 million for fiscal 2009.
